Same drug, thousands of prices: Crossing Medicare’s Catastrophic Coverage finish line
Ben LinkMedicare, PBM, Part D, Copaxone, Inflation Reduction Act, Catastrophic Coverage, IRA, NADAC, Mark Cuban, MFP, Januvia, Novolog, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, Imbruvica, WAC, Express Scripts, CVS, Optum, Kaiser, 340B
Medicare’s addiction to disconnected drug prices
Ben LinkGeneric, Medicare, PBM, Part D, AWP, dispensing fee, Transparency in Coverage, Suboxone, Buprenorphine-naloxone, opioid use disorder, addiction treatment, NADAC, Medicaid
How Mark Cuban reveals hidden costs of variable drug prices in Medicare
Ben LinkGeneric, Medicare, PBM, Mark Cuban, Cost Plus Drugs, Part D, imatinib, Costco, CVS, Cigna, UnitedHealth
Money from Sick People Part IV: Paying a Premium for Drug Pricing Irregularity
Ben LinkList prices, WAC, Insulin, Lantus, PBM, Humalog, Rutledge v PCMA, diabetes, Inflation Reduction Act, Apidra, Novolog, Levemir, Medicare, Part D
How PBMs distort and undermine specialty drug pricing guarantees
Ben LinkSpecialty, WAC, AWP, specialty drugs, PBM, Brand drugs, Generic drugs, Effective rate, NADAC, Linda Cahn, CVS, Express Scripts, Optum, Emgality, Retevmo, Imatinib, Gleevec, Hyalgan, Medicaid, Medicare, Mark Cuban, Ohio
Brand drug launch prices: A game of perspective
Ben LinkRebates, Launch, drug prices, Brand drugs, Inflation Reduction Act, Medicare, Lyrica, WAC, Adbry, Firazyr, Zolgensma, Trikafta, CPI, List prices
Medicare hits $200 billion in gross drug spend: Who gets the blame?
Ben LinkMedicare, Part D, Brand drugs, Generic drugs, Specialty, DIR fees, Rebates, PBM, Eliquis, Revlimid, Xarelto, Januvia, Trulicity, Imbruvica, Lantus, Jardiance, Humira, Ibrance, NADAC, atorvastatin, WAC
Wreck-fidera: How Medicare Part D has hidden the benefits of generic competition for a blockbuster Multiple Sclerosis treatment
Ben LinkMedicare, Copaxone, Teva, Rebates, Tecfidera, Biogen, Multiple Sclerosis, WAC, Mylan, NADAC, specialty drugs, Kaiser, CVS, UnitedHealthcare, Cigna, Anthem, Humana, Centene, DIR fees, AWP, Plan Finder
The Flawed Design of Medicare Part D: A Copaxone Case Study
Ben LinkCopaxone, glatiramer, Medicare, Part D, PBM, specialty drugs, Gleevec, ACA, Drug prices, Teva, Mylan, Sandoz, Deductible, Rebates, DIR fees
